文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.

作者信息

Le Xiuning, Rangachari Deepa, Costa Daniel B

机构信息

Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, US.

出版信息

J Thorac Dis. 2017 Sep;9(9):2812-2818. doi: 10.21037/jtd.2017.08.79.

DOI:10.21037/jtd.2017.08.79
PMID:29221246
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5708368/
Abstract
摘要

相似文献

[1]
Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.

J Thorac Dis. 2017-9

[2]
Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?

Cancer Chemother Pharmacol. 2014-10

[3]
"My Patient Was Diagnosed With Nontargetable Advanced Non-Small Cell Lung Cancer. What Now?" Diagnosis and Initial Treatment Options for Newly Diagnosed Patients With Advanced NSCLC.

Am Soc Clin Oncol Educ Book. 2018-5-23

[4]
Optimizing Patient Selection to Maximize Drug Efficacy: the Expanding Role of Pharmacogenomics in the Clinical Development of Pembrolizumab for the Treatment of Non-small Cell Lung Cancer.

Clin Ther. 2019-4-25

[5]
Is intramuscular morphine satisfying frontline medical personnels' requirement for battlefield analgesia in Helmand Province, Afghanistan? A questionnaire study.

Br J Pain. 2015-5

[6]
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.

Cancer Treat Rev. 2017-10-23

[7]
Out of the darkness and into the light: New strategies for improving treatments for locally advanced non-small cell lung cancer.

Cancer Lett. 2018-2-6

[8]
Immunotherapy in treatment naïve advanced non-small cell lung cancer.

J Thorac Dis. 2018-2

[9]
Management of dog bites by frontline service providers in primary healthcare facilities in the Greater Accra Region of Ghana, 2014-2015.

Infect Dis Poverty. 2018-2-28

[10]
Chemotherapy in metastatic and locally advanced non-small cell lung cancer.

Semin Surg Oncol. 2003

引用本文的文献

[1]
Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer.

Cancer. 2019-8-5

本文引用的文献

[1]
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.

J Thorac Oncol. 2017-11

[2]
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

Lancet Oncol. 2017-6-9

[3]
Ascending role of next-generation ALK inhibitors.

Lancet Oncol. 2017-7

[4]
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

N Engl J Med. 2017-6-6

[5]
Scientific Advances in Thoracic Oncology 2016.

J Thorac Oncol. 2017-6-1

[6]
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

Lancet. 2017-5-10

[7]
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

J Clin Oncol. 2017-5-5

[8]
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2017-4

[9]
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Lancet. 2017-1-24

[10]
Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling?

Cell Cycle. 2017-1-2

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索